[go: up one dir, main page]

BR0314713A - Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines. - Google Patents

Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.

Info

Publication number
BR0314713A
BR0314713A BR0314713-4A BR0314713A BR0314713A BR 0314713 A BR0314713 A BR 0314713A BR 0314713 A BR0314713 A BR 0314713A BR 0314713 A BR0314713 A BR 0314713A
Authority
BR
Brazil
Prior art keywords
treatment
reagents
diseases
processes
disorders associated
Prior art date
Application number
BR0314713-4A
Other languages
Portuguese (pt)
Inventor
Brendan Smith
Jason Fong
Benjamin A Auspitz
M James Nichols
Grant R Zimmermann
Bradley B Brasher
Noah Sachs
Todd W Chappell
Palaniyandi Manivasakam
Curtis Keith
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314713(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of BR0314713A publication Critical patent/BR0314713A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PROCESSOS E REAGENTES PARA O TRATAMENTO DE DOENçAS E DISTúRBIOS ASSOCIADOS COM NìVEIS AUMENTADOS DE CITOCINAS PRó-INFLAMATóRIAS". A invenção refere-se a um processo para tratar um paciente diagnosticado com, ou em risco de desenvolver um distúrbio imunoinflamatório pela administração de um SSRI ou um análogo ou metabólito do mesmo e, opcionalmente, um corticosteróide ou outro composto ao paciente. A invenção também caracteriza uma composição farmacêutica contendo um SSRI ou análogo ou metabólito do mesmo e um costicoesteróide ou outro composto para o tratamento ou prevenção de um distúrbio imunoinflamatório."PROCESSES AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PRO-INFLAMMATORY CYTOKINES". The invention relates to a method of treating a patient diagnosed with or at risk of developing an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and optionally a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a costicosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

BR0314713-4A 2002-09-24 2003-09-24 Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines. BR0314713A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US41726102P 2002-10-09 2002-10-09
US42742402P 2002-11-19 2002-11-19
US42752602P 2002-11-19 2002-11-19
US46475303P 2003-04-23 2003-04-23
PCT/US2003/030156 WO2004030618A2 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Publications (1)

Publication Number Publication Date
BR0314713A true BR0314713A (en) 2005-07-26

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314713-4A BR0314713A (en) 2002-09-24 2003-09-24 Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.

Country Status (12)

Country Link
EP (1) EP1553955A4 (en)
JP (1) JP2006503905A (en)
AR (1) AR041386A1 (en)
AU (1) AU2003299196A1 (en)
BR (1) BR0314713A (en)
CA (1) CA2509526A1 (en)
HR (1) HRP20050355A2 (en)
IS (1) IS7811A (en)
MX (1) MXPA05003152A (en)
NO (1) NO20051669L (en)
TW (1) TW200422042A (en)
WO (1) WO2004030618A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL378108A1 (en) * 2003-02-14 2006-03-06 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
MXPA06003320A (en) * 2003-09-24 2006-06-08 Combinatorx Inc Therapeutic regimens for administering drug combinations.
CA2566861A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
US20080255074A1 (en) * 2004-11-19 2008-10-16 N.V. Organon Drug Combination Comprising A Selective Serotonin Reuptake Inhibitor And A Glucocorticoid Receptor Antagonist For The Treatment Of Depression
MY147864A (en) * 2005-04-13 2013-01-31 Astion Dev As Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
JP4832806B2 (en) * 2005-06-03 2011-12-07 久光製薬株式会社 Transdermal formulation
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
ATE531362T1 (en) * 2006-09-08 2011-11-15 Ore Pharmaceuticals Inc METHOD FOR REDUCING OR RELIEVING INFLAMMATION IN THE DIGESTIVE TRACT
WO2008033754A2 (en) * 2006-09-11 2008-03-20 Duke University Xanthine derivatives in methods and compositions for the treatment of vascular depression
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
JP5740300B2 (en) * 2009-02-27 2015-06-24 久光製薬株式会社 Transdermal formulation
PT117765A (en) * 2022-01-28 2023-07-28 Faculdade De Farmacia Da Univ De Lisboa TOPICAL FORMULATION OF FLUVOXAMINE FOR THE TREATMENT OF PSORIASIS
TW202423434A (en) * 2022-10-07 2024-06-16 瑞士商歐庫利斯營運股份有限公司 Eye drop microsuspensions of mtor inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122139B2 (en) * 1991-10-15 2001-01-09 マラーキー，ミッシェル，エフ． Composition for treating late stage inflammatory response
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
AU3601897A (en) * 1996-07-15 1998-02-09 Alza Corporation Novel formulations for the administration of fluoxetine
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Also Published As

Publication number Publication date
NO20051669L (en) 2005-06-10
CA2509526A1 (en) 2004-04-15
AR041386A1 (en) 2005-05-18
TW200422042A (en) 2004-11-01
WO2004030618A3 (en) 2005-04-07
HRP20050355A2 (en) 2005-10-31
JP2006503905A (en) 2006-02-02
EP1553955A4 (en) 2008-11-05
EP1553955A2 (en) 2005-07-20
IS7811A (en) 2005-04-19
WO2004030618A2 (en) 2004-04-15
MXPA05003152A (en) 2006-04-27
AU2003299196A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
TW200509958A (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
BRPI0415397A (en) methods and reagents for the treatment of immunoinflammatory disorders
BRPI0414435A (en) methods and reagents for the treatment of immunoinflammatory disorders
BR0314713A (en) Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.
BRPI0512213A (en) method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound
DE60331236D1 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DIABETES
DE60216830D1 (en) Pharmaceutical compositions for the treatment of disorders of the CNS or other diseases
BR0211062A (en) Combinations for the treatment of inflammatory disorders
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
BR0213540A (en) Compounds, method for treating a patient's illness or disorder and a pharmaceutical composition comprising them
NO20062363L (en) Methods and Reagents for the Treatment of Inflammatory Disorders
BR0213100A (en) Combinations for the treatment of immunoinflammatory disorders
WO2004043341A3 (en) Treatment for hemorrhagic shock
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
WO2005079284A3 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
BRPI0411176A (en) pharmaceutical combination consisting of modafinil and another drug
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions
BR0313413A (en) Use of beta amyloid vaccination together with a selective cox-2 inhibitor for the treatment of alzheimer's disease
BRPI0416882A (en) compound, pharmaceutical composition, method of treating a disorder, and use of a compound
UA89753C2 (en) Use of a modafinil and an antidepressant for the treatment of depression and for decreasing the onset time of an antidepressant
BR9814867A (en) Method for treating disease-related or drug-induced dyskinesias
BRPI0414688A (en) anti-il-2 receptor respiratory disease treatment
BR0311180A (en) Methods for treating respiratory diseases and conditions using a selective inhibitor of inos
DE60321954D1 (en) SYNERGISTIC COMPOSITION CONTAINING ROFLUMILAST AND (R, R) -FORMOTEROL

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: COMBINATORX, INCORPORATED (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060103181/RJ DE 11/07/2006.

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/56; A61P 37/00

Ipc: A61K 31/56 (2011.01), A61P 37/00 (2011.01)

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.